3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers


Keynote Speakers

KL01 - Attenuating Oncogenic Transcription with Small Molecules
Prof. Angela KOEHLERProf. Angela KOEHLER
(MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States)

Read more
KL03 - Functionalization of N-Heterocycles using Li, Mg, and Zn Organometallics
Prof. Paul KNOCHELProf. Paul KNOCHEL
(LUDWIG MAXIMILIANS UNIVERSITY, Munich, Germany)

Read more
KL02 - Drug Discovery: Where are we Headed?
Dr Wendy YOUNGDr Wendy YOUNG
(MPM CAPITAL, Brisbane, CA, United States)

Read more

The "Catalytic Cycle" of Complex Molecule Synthesis and Methodology Development

IL23 - Flow-based Methods for Chemical Peptide and Protein Synthesis".
Prof. Nina HARTRAMPFProf. Nina HARTRAMPF
(UNIVERSITY OF ZURICH, Zürich, Switzerland)

Read more
IL24 - Prins Cyclization in Natural Product Synthesis
Prof. Ang LIProf. Ang LI
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China)

Read more
IL25 - Taming Multifaceted Nickel Catalysts: An Academic Fascination
Prof. Ruben MARTINProf. Ruben MARTIN
(INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA, Tarragona, Spain)

Read more
IL26 - Computationally Augmented Total Synthesis
Dr Timothy NEWHOUSEDr Timothy NEWHOUSE
(YALE UNIVERSITY, New Haven, United States)

Read more

Automation and Machine Learning Applications for Medicinal Chemistry

IL09 - Enabling Fragment-based Drug Discovery (FBDD) with Automated Synthesis Technologies
Dr Rachel GRAINGERDr Rachel GRAINGER
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Read more
IL10 - Rapid Development of Robust Reactions and Multi-Step Syntheses
Prof. Alexei LAPKINProf. Alexei LAPKIN
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

Read more
IL11 - High-Throughput Experimentation Capabilities to Accelerate Discovery Chemistry
Dr Iulia STRAMBEANUDr Iulia STRAMBEANU
(JOHNSON AND JOHNSON, King of Prussia, United States)

Read more

Methodologies to Understand Cellular Target Interaction

IL01 - Intracellular Oligonucleotide Distribution and Protein Binding
Dr Alice GHIDINIDr Alice GHIDINI
(ASTRAZENECA, Gothenburg, Sweden)

Read more
IL04 - Lessons in Transcellular Membrane Permeability Re-Learned
Dr Mike HANNDr Mike HANN
(GSK MEDICINES RESEARCH CENTRE, Stevenage, United Kingdom)

Read more
IL03 - Molecular Chameleonicity and Cell Permeability of Drugs and PROTACs in the bRo5 Space
Prof. Jan KIHLBERGProf. Jan KIHLBERG
(UPPSALA UNIVERSITY, Uppsala, Sweden)

Read more
IL02 - Monitoring Drug Selectivity and Target Engagement Across Systems – Thermal Shift Assay in Drug Discovery
Dr Anna RUTKOWSKA-KLUTEDr Anna RUTKOWSKA-KLUTE
(GSK, Heidelberg, Germany)

Read more

Understanding PK and PK/PD relationships in drug discovery - Target Mediated Drug Disposition

IL17 - Concept of Pharmacologic Target-Mediated Drug Disposition (TMDD) in Large-Molecule and Small-Molecule Compounds
Prof. Guohua ANProf. Guohua AN
(THE UNIVERSITY OF IOWA COLLEGE OF PHARMACY, Iowa City, United States)

Read more
IL18 - Understanding the PKPD and ADME of PF-07059013: An Allosteric Modulator of a High Abundance Target
Dr Kevin BEAUMONTDr Kevin BEAUMONT
(ASTRAZENECA, Cambridge, United Kingdom)

Read more
IL16 - General Introduction to TMDD
Dr David FAIRMANDr David FAIRMAN
(GSK, Cambridge, United Kingdom)

Read more
IL19 - Importance of Mechanistic Models in AHD Prediction (IL)
Dr Birgit SCHOEBERLDr Birgit SCHOEBERL
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Cambridge, MA, United States)

Read more

Drug Discovery Tales (II)

OC06 - Towards the Design of Cell Division Cycle 25 Phosphatases Inhibitors as Anticancer Agents
Dr Carmen CERCHIADr Carmen CERCHIA
(UNIVERSITY OF NAPLES FEDERICO II, Naples, Italy)

Read more
OC04 - Dissociative Inhibitors of Thymidylate Synthase Homodimer Accelerate its Proteasomal Degradation and Inhibit Cancer Growth in Vivo
Prof. Maria Paola COSTIProf. Maria Paola COSTI
(UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy)

Read more
OC05 - Rational Design of Light-Controlled Bioactive Compounds for Photopharmacology
Mr Piermichele KOBAURIMr Piermichele KOBAURI
(UNIVERSITY OF GRONINGEN FSSC, Groningen, The Netherlands)

Read more
OC03 - Discovery of a Selective ALK2 Kinase Inhibitor for the Treatment of a Rare Genetic Bone Disease
Dr Thomas ULLRICHDr Thomas ULLRICH
(NOVARTIS PHARMA AG, Basel, Switzerland)

Read more

Increasing sp3 Fragment Options: Advances in the Synthesis of Small Ring Systems

IL12 - Exploring and exploiting propellanes
Prof. Ed ANDERSONProf. Ed ANDERSON
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
IL15 - No Strain, No Gain: Advances in the Synthesis and Design of New Classes of Building Blocks
Prof. Kevin BROWNProf. Kevin BROWN
(INDIANA UNIVERSITY, Bloomington, United States)

Read more
IL13 - The Next Generation of BCPs: Exploring Substitutions on the Bridge
Dr Xiaoshen MADr Xiaoshen MA
(MERCK & CO., INC, Boston, United States)

Read more
IL14 - Synthesis and Functionalization of Cyclopropane Derivatives
Dr Sophie ROUSSEAUXDr Sophie ROUSSEAUX
(UNIVERSITY OF TORONTO, Toronto, Canada)

Read more

Covalent Targeting: Innovating for the Future

IL22 - Studies with Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors
Dr Agustin CASIMIRO-GARCIADr Agustin CASIMIRO-GARCIA
(PFIZER, United States)

Read more
IL20 - Lysine-Targeting Covalent Inhibitors
Dr Matthew CHEESEMANDr Matthew CHEESEMAN
(THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom)

Read more
IL21 - Reversible-covalent Inhibitors of the Kinase Activity of FGFR4
Dr Robin FAIRHURSTDr Robin FAIRHURST
(NOVARTIS, Basel, Switzerland)

Read more

Drug Discovery Tales (I)

OC01 - Design and Synthesis of Novel RNA Binders for Therapeutic Applications
Ms Maurinne BONNETMs Maurinne BONNET
(ICN, NICE, France)

Read more
OC02 - Is Resistance Futile? Discovery of Clinical Candidate AZD3229, A Pan-Mutant C-KIT Inhibitor
Dr James SMITHDr James SMITH
(ASTRAZENECA, Cambridge, United Kingdom)

Read more

Targeting Unstructured Proteins

IL05 - Innovative Strategies to Target Non-Coding RNAs with Synthetic Ligands
Dr Maria DUCADr Maria DUCA
(UNIVERSITY OF CÔTE D'AZUR, Nice, France)

Read more
IL07 - Drugging RNA – A Structure-based Approach
Dr Jacques DUMASDr Jacques DUMAS
(ARRAKIS THERAPEUTICS, Boston, United States)

Read more
IL06 - Targeting Transcription Factors for Treating Human Cancers and Auto Immune and Inflammatory Diseases
Dr Doriano FABBRODr Doriano FABBRO
(CELLESTIA BIOTECH AG, Basel , Switzerland)

Read more
IL08 - Design of Zotatifin (eFT226), a First-in-Class Inhibitor of the RNA Helicase eIF4A
Dr Christian NILEWSKIDr Christian NILEWSKI
(GENENTECH, South San Francisco, United States)

Read more

EFMC Sponsored Event

Silver Sponsors

Bronze Sponsor

Copyright 2022 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys